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SUMMARY
Objectives. This study is part of a programme on 
reduction of postpartum haemorrhage. Buccal 
oxytocin and desamino-oxytocin administration 
with a favourable effect on both blood loss and 
maternal morbidity and mortality were regarded 
as possible treatments for use in tropical coun­
tries. The stability of buccal oxytocin and 
desamino-oxytocin under tropical conditions was 
unknown and therefore tested in this study.
Study methods. The 'experimental shelf lives' 
of buccal oxytocin and desamino-oxytocin were 
examined by exposing the tablets to seven 
artificially controlled conditions. Samples were 
analysed by high performance liquid chromatog­
raphy to determine the content of oxytocin and 
desamino-oxytocin at nine different times during 
the period of 1 year.
Results. Oxytocin and desamino-oxytocin are 
fairly stable under refrigeration. Instability for 
both drugs was detectable after 20 weeks' storage 
under humid conditions, independent of tempera­
ture. Desamino-oxytocin is more sensitive to light 
exposure; its concentration declines to 55*6% of 
the stated amount after 1 year of exposure to 
light compared to 85% in the case of oxytocin. 
Oxytocin packaged as supplied by the manufac­
turer were stable for 21 weeks when exposed to 
simulated humid (75% relative humidity) condi­
tions. At 40°C and 25% relative humidity there is 
no difference in stability between tablets in sealed 
aluminium packs as supplied by the manufacturer 
and unpackaged tablets.
Conclusions. Tropical conditions make oxytocin 
and desamino-oxytocin tablets unstable, with
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humidity as the most adverse factor. The oxytocin 
tablets were partially protected from the 
harmful effect of humidity by sealed aluminium 
package.
INTRODUCTION
Postpartum haemorrhage (PPH) is still one of the most 
common causes of maternal death especially in third 
world countries (1—3). Emergency referral of severe 
bleeding is difficult to arrange in these countries. 
Therefore, prevention and management of PPH at all 
levels of obstetric care is mandatory. For prevention 
and management of PPH, routine use of oxytocics in 
the postpartum period is advocated (4). Compared to 
other oxytocics, oxytocin is the preferred drug for 
preventing and managing blood loss after childbirth 
because it is more stable under (simulated) tropical 
conditions and gives fewer side-effects (3, 5, 6). 
Oxytocin is usually given intramuscularly but is 
also available as tablets for buccal and sublingual 
administration.
To be used in tropical climates, drugs have to be 
stable and easy to administer when used by 
untrained people. Moreover, the route of choice 
is by mouth. Recent stability studies of oxytocin 
in an injectable form showed marked deterioration 
upon exposure to elevated temperatures and light 
(7—9).
The aim of the present investigation was to exam­
ine the stability of oxytocin and desamino-oxytocin 
tablets under simulated tropical conditions to deter­
mine whether it is feasible to replace the parenteral 
oxytocics by sublingual administration. The stability 
of the compounds have been assessed, using 'experi­
mental shelf life' methodology to demonstrate 
whether the drugs can be transported and stored 
without the loss of potency.
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M ATERIAL AND M ETH O D S 
S tu d y  design
Definitions used in the study are given in Table 1. In 
the design of this study, use is made of the recom­
mendations laid down in the Protocol of the Research 
of the Stability of Drugs in Aqueous Solutions by the 
Dutch Society of Hospital Pharmacists (10). We 
simulated seven tropical conditions (Table 2). The 
following tablets were examined: buccal oxytocin 
tablets, 200 IU, batch number 00111061, and buccal 
desamino-oxytocin tablets, 50 IU, batch number 075 
MFD 0691. Oxytocin was received in air-tight alu­
minium packages. These sealed packages are presumed 
to be light-resistant and humidity-proof. The packages 
were exposed to tests III, IV and V (Table 2). During 
storage tests, the tablets were exposed to the intended
conditions, in identical transparent tins. For each 
sampling period (weeks 0-52), a different tin was used. 
One batch from each manufacturer was examined. To 
achieve acceptable statistical power, four tablets were 
assayed per storage condition per manufacturer. At 
weeks 0 and 52, 20 tablets per storage condition per 
manufacturer have been investigated. Tablet weight, 
integrity and colour were assessed prior to assay of 
drug content.
Assay m ethod
High performance liquid chromatography (HPLC) was 
used as the assay method (11—16). In short, the HPLC 
analysis was as follows. The column was 25 x 4*6 mm 
ID packed with Spherisorb 5-ODS (particle size, 5 |im; 
Chrompack, Middelburg, The Netherlands) with a
m m
Stability
Batch
Shelf life
Experimental shelf life
Pharmaceutical requirements
The extent to which a product retains, within 
specified limits, and throughout its period of 
storage and use (i,e, its shelf life), the same 
properties and characteristics it possessed at the 
time of its manufacture (Ref. 19)
The homogeneously produced number of drugs 
(Ref. 19)
The time during which at least 90% of the declared 
dose of the active ingredient is still present in the 
product (f90 or time for 10% loss of active 
ingredient) (Refs 18, 20)
The period of time during which under defined 
experimental conditions a batch fulfils the 
requirements (Ref. 17)
The level of active ingredient has to be within 
90-110% of the stated amount to fulfil the 
pharmaceutical requirements (Ref. 19)
Table 1. Definitions used in study
Storage condition
Table 2. Definitions of simulated 
tropical conditions
Test Light exposure Temperature Relative humidity Notation
I Dark 6-10 °C 83-85%: ambient Dó/83
II Dark 20 °C* 75%+ D20/75
III Dark 30°C* 45%+ D 3 0/45
IV Dark 30°C* 75%+ D30/75
V Dark 40°C* 12-28%: ambient D 40/25
VI Dark 40°C* 75%** D40/75
VII Lights 20-25 °C§ 20-35%: ambient L20/30
^Specified within ±  2°C 
tSpecified within ±  5%.
^Fluorescent white light, 450-650 nm; 
1000 lx.
§Room temperature.
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guard column (75 x 2-1 mm ID) packed with 10-)Lim 
pellicular reversed phase (Chrompack, catalogue no. 
02&652>). An injection loop of 100 jllI was used. The 
mobile phase consisted of a mixture of acetonitrile in 
H20  (1:1) as solvent A and 0*1 M monobasic KH2P 0 4 
buffer as solvent B; the mixture consisted of 55% of 
A and 45%  of B. All reagents were of analytical 
grade (Merck, Darmstadt, Germany). The flow rate 
was 1-2 ml/min. Detection wavelength was 225 nm, 
The retention time was 6-7 min, the capacity factor 
was 1-84 and the analysis was carried out at room 
temperature. The detection limit of oxytocin and 
desamino-oxytocin in water was 0-50 ng both at a 
signal to noise ratio of 1:3. The inter-day variation was 
1*95% for oxytocin and 3*19% for desamino-oxytocin 
and the intra-day variation was 1-06% for oxytocin 
and 1-96% for desamino-oxytocin.
The data were analysed in a general linear model 
and a logistic regression model for ordinal response 
variables.
RESULTS
The raw data of the simulation study are published in 
World Health Organization/Drug Action Programme 
Report (16). At f=0, the initial drug content of 20 
tablets of each brand fulfilled the pharmaceutical 
requirements. The results of test 1 (least extreme 
condition) and test VI (most extreme condition) for 
both oxytocin and desamino-oxytocin tablets are 
shown in Fig. 1.
Oxytocin
Active ingredient. The level of active ingredient in the 
product declines gradually when stored under all 
conditions studied. The stated amount was 200 IU/ 
tablet. Under refrigerated storage (D6/83), the least 
extreme condition, oxytocin remains stable for more 
than 23 weeks. At 40°C and 75°C relative humidity 
in the dark (D40/75), the most extreme condition, 
oxytocin was less stable, with only 89*4% 
(178-8 d= 2*90 lU/tablet) of the stated amount left after 
14 weeks (Fig. 1).
Test IV (D30/75), very humid, and test V (D40/25), 
hot and dry, demonstrate the influence of humidity. At 
30°C and 75% relative humidity in the darkness 
(D30/75), the product retained only 41*2% (82*34 IU/ 
tablet) of the stated amount of the active ingredient
Time (weeks)
Fig, 1. Stability of oral oxytocin and desamino-oxytocin 
exposed to least (I) and most (VI) extreme conditions. DOT, 
desamino-oxytocin; OT, oxytocin; D6/83, test I: 6°C, 83% 
RH and darkness; D40/75, test VI: 40°C, 75% RH and 
darkness.
after 33 weeks. Exposed to 40°C and 25% relative 
humidity in the dark (D40/25), 82*8% (165-6 ±  3-5-0 
IU/tablet) of the stated amount of active ingredient 
remained after 53 weeks. In these tests humidity had a 
greater influence on stability than temperature. Tablets 
packed as supplied by the manufacturer fulfilled 
pharmaceutical requirements for 23 weeks at 75% 
relative humidity, and 80-7% remained after 33 weeks 
of exposure.
The influence of light was shown in test II (D20/75) 
and test VII (L20/30). After 23 weeks of exposure in 
test II, only 17-5% (35*0 U/tablet) of the stated amount 
remained, whereas with full exposure to light (test 
VII), even after 53 weeks' exposure, 85% (170-0 U/ 
tablet) of the stated amount remained.
Desamino-oxytocin
The drug was unstable under all conditions studied. 
Under refrigeration (D6/83), the least extreme condi­
tion, desamino-oxytocin remained stable for more than 
14 weeks. At 40°C and 75% relative humidity in the 
dark (D40/75), the most extreme condition, the 
desamino-oxytocin is less stable, with only 67*2% 
(33-6 dz 3-38 IU/tablet) of the stated amount of the 
active ingredient left after 14 weeks (Fig. 1).
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Test IV (D30/75), humid, and test V (D40¡25), hot
and dry, showed that the influence of humidity on 
stability was more marked than that of temperature. 
At 30°C and 75% relative humidity in the dark 
(D30/75), the product has only 37-2% (18-6 db 1-35 IU/ 
tablet) of the stated amount of the active in gradient 
left after 33 weeks. A t 40°C and 25% relative humidity 
in the dark (D40/25), 60*9% (30*5 ±  1*58 IU/tablet) of 
the stated amount of active ingredient was left after 53 
weeks.
Under all conditions (except test III) oxytocin is 
more stable than desamino-oxytocin.
No differences in weight larger than 0*1 mg were 
noticed during the study. Discolouration occurred in 
the tablets especially when stored under humid condi­
tions. Growth of mould was observed on some tablets 
stored under humid conditions (tests II, IV and VI).
DISCUSSION
Buccal oxytocin and desamino-oxytocin tablets have 
been withdrawn from the market as greater control in 
induction and augmentation of labour is achieved by 
intravenous or intramuscular administrations of oxy­
tocin. However, those tablets have never been used as 
prophylactic agents in the prevention of PPH. The 
stability of those tablets was unknown and hence the 
reason for undertaking the present study. We have 
been able to examine just one brand of desamino- 
oxytocin, batch 075 MFD 0691, and one brand of 
oxytocin, batch number: 001061.
Sampling points in time
Long-term stability studies under 'temperate climate' 
conditions normally last 5 years (17). The tablets in 
this study have been subjected to conditions that are 
more extreme to speed up the degradation process. 
The stability test was performed for a period of 1 year 
only, because in actual practice in tropical countries, 
tablets are not stored for longer periods. Loss of 
potency by water absorption was expected to occur 
especially in the early stages (18). Therefore, the 
sampling was done more frequently in the early stages 
and eight samples were made in the first 21 weeks 
(10).
Both oxytocin and desamino-oxytocin brands failed 
the pharmaceutical requirements for stability within 
±  23 weeks. When packed as supplied by the
manufacturer, stability is improved, but even then, 
after 33 weeks of exposure in test IV (D30/75), only 
80-7% of the active ingredient remained. This is too 
short a shelf life in tropical countries, considering the 
fact that the time needed for transportation is already 
several weeks. Humidity is the most adverse factor 
compared with both temperature and light.
CONCLUSIONS AND RECOMMENDATIONS
Oxytocin and desamino-oxytocin tablets have too 
short a shelf life for use in tropical countries. Neither 
of the preparations available are suitable for use as 
prophylactic agents in the prevention of PPH.
Currently available buccal oxytocin and desamino- 
oxytocin tablets are no alternatives to the parenteral 
products for PPH prevention. The formulation of a 
stable non-injectable alternative to oxytocin injection 
is advocated.
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